Chapter 57: Drugs for Hemophilia

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about a medical diagnosis, there's this expectation of like clinical precision.

Right, yeah.

It feels like engineering.

You break your arm, the x -ray shows that jagged white line, and the doctor just points and says, you know, there it is, broken.

It's binary.

And, I mean, it's comforting because we like things to be visible and easily categorized.

You apply a cast, the bone knits, and problem solved.

Exactly.

But then you look at something like the human blood clotting cascade, and suddenly you aren't looking at a clean x -ray anymore.

You're looking at this incredibly complex, intimidating Rube Goldberg machine.

Oh, I love that analogy.

You know those machines?

A marble rolls down a ramp, knocks over a domino, the domino cuts a string, the string drops a boot,

and well, the boot finally flips a switch.

That is the perfect visual for hemostasis.

It is a highly choreographed sequential chain reaction where every single moving part relies entirely on the part that came right before it.

And today, we are going to isolate the exact missing gears in that machine.

So welcome to today's Deep Dive.

We are unpacking the pharmacology of hemophilia, specifically drawing from Lynn's Pharmacology for Nursing Care, Chapter 57.

Which is a heavy chapter.

It really is.

So our mission today is to translate all this dense drug information,

the mechanisms, the risks, and the nursing implications into plain language.

We're stepping right into the shoes of a nursing student seeing this for the first time.

Yeah, we need to connect the dots between the underlying physiology and the therapeutic goals.

Because if you understand the mechanism, if you know exactly why the body is failing to stop a bleed, the reasoning behind the medication decisions makes perfect sense.

Let's start with the broken mechanism itself.

Before we can treat a patient, we have to understand exactly what goes wrong in the body.

Hemostasis, you know, the process of stopping bleeding, happens in two main stages.

First you get a platelet plug.

Right.

The platelets rush to the side of the injury and clump together to plug the hole, which crucially works perfectly fine in a patient with hemophilia.

The platelets arrive and do their job.

So if the plug forms normally, I think the natural question is why does the bleeding continue?

Well, because that initial platelet plug is fragile.

It needs reinforcement.

That's stage two, the production of fibrin.

Fibrin, okay.

Yeah, fibrin is this tough stringy protein that acts like a net.

It weaves through the platelets to lock them in place and hold the clot together.

In hemophilia, fibrin production fails.

So the Rube Goldberg machine breaks down right before the net can be deployed.

Exactly.

The failure happens deep within what we call the contact activation pathway, also known as the intrinsic pathway.

Hemophilia A is a deficiency of clotting factor eighth, which is also called anti -hemophilic factor.

Right.

And hemophilia B?

That's a deficiency of clotting factor 9x, the Christmas factor.

Named after Steven Christmas, the first boy diagnosed with it in the 1950s, not the holiday, right?

Spot on.

So both of these factors, 8th and IX, they sit right beside each other in that intrinsic pathway.

In their activated forms, they have one job.

They are absolutely required to catalyze the conversion of factor X into its active form.

And without activated factor X, prothrombin can't become thrombin.

And without thrombin, fibrinogen can't become that vital fiber net.

The machine just stops.

The clot is delayed and bleeding continues much, much longer than normal.

Just to give a sense of scale to this for you listening, hemophilia A is about six times more common.

It occurs in about 1 in 5 ,000 males,

while hemophilia B is 1 in 30 ,000 males.

And it is almost exclusively seen in males because of how the genetics work.

Right.

Because the genes for both factors 8 and IX are recessive and carried on the X chromosome.

Males only have one X chromosome, so if they inherit that defective gene, they have the disease.

And females have two X chromosomes.

Exactly.

A female with one defective gene has a functioning backup gene on her other X chromosome, making her an asymptomatic carrier.

Though the text does note two extremely rare exceptions where females can be symptomatic.

That happens if they inherit defective genes on both X chromosomes, or if their healthy gene somehow gets inactivated.

Yeah, it's very rare.

But generally speaking, a carrier mother has a 50 -50 chance of passing the disease to her son and a 50 -50 chance of passing the carrier status to her daughter.

And the severity of the disease completely dictates what the patient's life looks like.

Severity is categorized strictly by the concentration of the clotting factor in their blood, right?

Severe hemophilia means the factor level is less than 1 % of normal.

Less than 1 %?

That sounds like living on a knife's edge.

It is.

These patients can experience life -threatening hemorrhage from incredibly minor trauma.

But the hallmark of severe hemophilia is frequent,

spontaneous bleeding into the joints, most commonly the knees, elbows, and ankles.

And blood is highly irritating to the synovial tissue inside a joint, isn't it?

Oh, incredibly.

With repeated bleeding episodes, that intense inflammation actually leads to permanent crippling joint destruction.

Wow.

Then you have moderate hemophilia, where the factor level is between 1 % and 5 % of normal.

Bleeding from everyday minor trauma is unlikely here, but serious trauma or surgery will cause significant issues.

And occasional joint bleeding happens, but much less often.

Right.

Finally, mild hemophilia is when factor levels are between 6 % and 49 % of normal.

These patients might go years without knowing they have it.

They rarely have spontaneous bleeds.

Joint bleeding usually only happens if provoked by a severe injury or, like, a major surgery.

So knowing the stakes, how do we handle general care?

Say a patient comes in with a painful joint bleed.

You obviously need to manage their pain, but their clotting cascade is already compromised.

Well, for mild pain, acetaminophen, sotylenol is the absolute drug of choice.

Because there is a massive unbreakable rule here, which is NO aspirin.

Never.

Aspirin causes irreversible inhibition of platelet aggregation.

We just established that their fibrin net is broken, right?

So their fragile platelet plug is the only defense they have.

We cannot compromise those platelets.

Plus, aspirin induces gastrointestinal ulceration, creating a brand new bleeding site.

What about traditional first -generation NSAIDs like ibuprofen?

They're also, I mean, they reversibly inhibit platelets, but the GI bleed risk is still way too high.

But obviously you can't just leave them in pain if Tylenol isn't cutting it.

I know traditional NSAIDs are out, but what about the newer KeOX2 inhibitors like Celecoxib?

Since they act a bit differently, are them safe?

Yeah, KeOX2 inhibitors don't suppress platelet aggregation and they carry a significantly lower risk of causing stomach ulcers.

So they are widely considered safe and clearly preferred over traditional NSAIDs for these patients.

Even though large -scale definitive trials haven't officially rubber -stamped them yet, right?

Exactly.

It's the standard of care in practice.

Got it.

Another general care aspect is immunizations.

Children still need their normal vaccine schedule.

I read that instead of the usual intramuscular injections, some clinicians prefer subcutaneous injections to avoid causing a deep muscle bleed.

There's a debate there.

Intramuscular is still generally preferred by many because subcutaneous efficacy isn't always as reliable.

Most patients tolerate the IM injection just fine if you apply firm, prolonged pressure to the site afterward.

Makes sense.

But the most crucial immunization detail is that all newly diagnosed patients absolutely must be vaccinated for hepatitis A and B.

Because their treatment is going to expose them to a lot of blood products over their lifetime.

Yeah.

Which brings us to the mainstay of treatment.

Factor VIII concentrates for hemophilia A.

The goal is simple, right?

Just replace the missing factor.

Simple in theory?

Incredibly complicated in practice.

Historically, replacing that factor was deeply unsafe.

Before 1985, factor VIII was extracted and concentrated from the pooled blood plasma of thousands of different donors.

Oh, right.

Tragically, nearly all people with hemophilia who received those treatments during that era contracted HIV, hepatitis C, or both from contaminated plasma.

It's one of the darkest chapters in medical history.

Today, the landscape is radically different, thankfully.

Donated plasma is rigorously screened for HIV, hepatitis A, B, C, and parvovirus B19.

They use advanced viral inactivation techniques like solvent detergent treatments for lipid -coated viruses.

Even with all those modern safeguards, though, plasma -derived products carry a lingering theoretical risk.

Non -lipid -coated viruses like hep A and parvovirus are harder to neutralize.

And there's the theoretical risk of prions, which cause Creutzfeldt -Jakob disease.

So because of those theoretical risks, the industry deliberately shifted toward recombinant factor VIII.

Meaning they produced the factor in a cell culture using recombinant DNA technology, completely bypassing human blood donors.

The text goes through four generations of this recombinant technology, and it's basically a story of trying to make the manufacturing process cleaner and less recognizable to the human immune system.

Right, so imagine you are trying to build a highly complex biological machine.

Generation I was built in a lab, but they used animal proteins, specifically bovine serum albumin from cows, and human serum albumin as nutrients in the culture and as stabilizers in the final vial.

And the problem is, injecting animal protein into a human can trigger an immune response.

The immune system spots the animal protein, flags it as foreign, and attacks the drug.

So Generation II refined the process.

They still used human albumin in the culture to help the cells grow, but they completely removed the bovine and human proteins from the final vial that goes into the patient.

A step up, but Generation III went even further.

No bovine or human proteins used anywhere, not in the culture, not in the vial.

And Generation IV is the current peak of this evolution.

Not only are there no animal or human proteins used, but they changed the host cells entirely.

Oh, what did they switch to?

The earlier generations used hamster cells as the biological factories.

Generation IV switched to a human embryonic kidney cell line.

Because the factor is produced by human cells, it folds and structures itself much more naturally.

It is significantly less immunogenic.

Meaning the patient's body is far less likely to reject it.

That's incredible.

And beyond just how it's made, there's been a massive quality of life upgrade in recent years with extended half -life, or EHL products.

Right, because traditional recombinant factors clear out of the bloodstream very quickly, requiring patients to endure multiple IV injections every single week.

Which is brutal.

It is.

EHL products solve this through bioengineering.

They fuse the factor VIII protein with something else, like the FC portion of an antibody or recombinant human albumin.

Or they use pedulation, attaching polyethylene glycol molecules to it.

So it basically acts as a shield.

Exactly.

It slows down the body's breakdown of the factor so it lasts much longer.

Patients might only need to dose every 7 to 10 days.

So how do we actually calculate and give these drugs?

The text outlines two main approaches.

On -demand and prophylactic.

On -demand is exactly what it sounds like.

A patient is actively bleeding or they are about to go into surgery.

You give the drug via slow -5E push over 5 to 10 minutes.

And the dosage completely depends on the severity of the bleed.

The goal is to elevate the factor in the blood to a specific target percentage of normal activity.

So for a minor joint bleed, the target activity level might be 40 % to 60 % of normal.

Right.

If they are going into major surgery, you want them fully armored, hitting 80 % to 100 % pre -op.

Here's where the math comes in.

As a nursing student, you have to calculate this dose.

The formula for factor 8 is that one unit of drug per kilogram of body weight raises the plasma activity level by 2%.

Okay, let me show you this.

Say I have a 50 -kilogram patient and they have a joint bleed.

So we want to reach a 40 % target activity level.

Okay.

Walk me through your calculation.

I multiply their weight, 50 kilos, by the target percentage, which is 40.

That gets me 2 ,000.

But since every one unit raises the level by 2%, I divide that 2 ,000 and a half.

So I need to administer 1 ,000 units of factor 8.

Spot on.

It's a reliable formula.

But of course, you always follow up by monitoring the clinical response to ensure the bleeding actually stops.

Okay.

That math makes sense for when someone is actively bleeding or heading into surgery.

But waiting for a bleed seems like a terrible game to catch up, especially with the risk of permanent joint damage.

Isn't there a way to just keep the levels high enough to prevent the bleed in the first place?

That is exactly what prophylactic therapy does.

It's scheduled therapy, primarily used for children with severe hemophilia.

The goal is to keep their baseline factor level strictly above 1 % of normal at all times.

Basically bumping them from severe to moderate status.

Yes.

That prevents those spontaneous bleeds and protects their joints from long -term destruction.

It's usually given every other day or three times a week.

And because that is a massive number of 5E pokes for a young child, they often surgically install a central venous access device, like a portica.

But having a permanent port introduces new risks, specifically severe infections and thrombosis, which nurses and parents have to monitor constantly.

We also need to highlight a critical safety alert regarding factor VIII concentrates.

Because they are complex proteins, they can cause allergic reactions.

Right.

And knowing the difference between a mild reaction and a life -threatening one is vital.

If the patient develops hives, a stuffy nose, a rash, or a low -grade fever that's mild, you manage it with an antihistamine like diphenhydramine.

But if they develop wheezing, tightness in the throat, shortness of breath, or sudden facial swelling, that is severe anaphylaxis.

It can be fatal rapidly.

The treatment of choice is to administer subcutaneous epinephrine immediately.

Good to know.

So we fixed the missing gear for hemophilia A.

But what if the patient is missing the other gear in that intrinsic pathway?

What if they have hemophilia B?

Does the same exact drug work?

No.

You cannot give factor VIII to a patient missing factor IXX.

The therapeutic narrative is similar.

You are still replacing the missing gear, but you need a specific factor IXX concentrate.

Recombinant DNA, specifically a drug called Benefix, is the agent of choice for its excellent safety profile.

And does the math change?

Let's say I have that same 50 -kilogram patient needing that same 40 % target, but for factor IXX, do I still just multiply 50 by 40 to get 2 ,000 and then divide by 2?

Hold on.

That is the crucial pharmacological difference.

With factor VIII, you get a 2 % bump.

But with factor IXX, one unit per kilogram only raises the plasma level by 1%.

You physically need twice as much factor IXX drug to achieve the same percentage increase in the blood.

Oh, wow.

So no dividing by 2.

50 kilos times the 40 % target equals 2 ,000 units of factor IXX.

Exactly.

The other major clinical difference is prophylactic timing.

Factor IXX naturally has a longer half -life in the body, 18 to 24 hours, compared to just 8 to 12 hours for factor VIII.

So because it sticks around longer, prophylactic dosing is generally just twice a week instead of three times.

Yes, exactly.

Now replacing the factor directly is the main strategy, but it isn't the only tool we have.

We can also trigger the body to use what it already has, or even mimic the cascade entirely.

Let's get into those.

First up in the non -factor therapies is Desmopressin, or DDAVP.

Let me guess why.

Like a sponge, right?

Desmopressin doesn't contain any actual clotting factor itself.

Its mechanism is that it forces the vascular endothelium, the lining of the blood vessels, to release stored factor VIII into the bloodstream.

That's a great way to look at it.

If you have severe hemophilia A, your sponge is completely dry.

You don't have any stored factor VIII to release, so squeezing it does nothing.

But if you have mild hemophilia A, your sponge is a little damp.

Desmopressin can squeeze out just enough endogenous factor VIII to stop a minor bleed or prep the patient for a small surgery.

And because it only releases factor VIII, it is completely useless for hemophilia B.

Correct.

It is much cheaper than factor concentrates and can be given IV or as an intranasal spray.

However, because it is fundamentally an antidiuretic hormone, nurses must monitor for fluid retention and hyponatremia.

Dangerously low sodium levels caused by water intoxication, basically.

Yeah, exactly.

Then we have antibody therapy, specifically emetesumab, brand name Hemlabra.

This mechanism is wild.

It's a brilliant feat of bioengineering.

Emetesumab is a bispecific monoclonal antibody.

Think back to that intrinsic pathway.

Normal factor VIII has one job at X as a bridge, grabbing factor IC with one hand and factor X with the other, bringing them together so cascade can continue.

And emetesumab is a synthetic bridge.

Yes.

It physically binds IexoNX together, perfectly mimicking the action of factor VIII, even though it looks completely different to the body.

But it means the body is far less likely to form an immune response against it.

But there's a massive nursing alert tied to this synthetic bridge, isn't there?

Yes, there is.

Because emetesumab alters the clotting cascade in a non -standard way, it completely warps standard co -regulation tests.

It will cause abnormal APTT and ACT laboratory values.

If a nurse draws those labs, they will look airifyingly inaccurate.

Totally.

Furthermore, there is a severe risk of thromboembolism blood clots if a patient on prophylactic emetesumab is given a specific bypassing agent called AICC.

We'll dig into why that happens with AICC in just a moment.

But first, the ultimate non -factor therapy, gene therapy.

The text highlights Veloctico gene Roxaparvovac, or Roctavian, which was pending FDA approval at the time of publication in 2023.

Right.

It uses a harmless AAV5 virus as a delivery vehicle.

It carries a healthy F8 gene directly into the patient's liver cells.

It essentially turns the liver into a factory to build the missing gear.

Precisely.

It represents a potential one -and -done cure, virtually eliminating the need for routine prophylaxis, but it comes with a staggering price tag of around $2 million for a single dose.

Yeah, that's steep.

So what happens when standard therapies fail?

Let's look at complications.

What happens when the clot breaks down too fast, or the body actively fights the treatment?

Let's start with clots dissolving prematurely.

Normally, when a clot has done its job, an enzyme called plasmin activates.

Plasmin acts like a pair of biochemical scissors, snipping up the fibrin meshwork to dissolve the clot and clear the vessel.

But in hemocilia, getting that net built in the first place was incredibly difficult.

If plasmin dissolves it too early, the bleeding starts all over again.

So we use anti -fibrinolytic agents, drugs like aminocaproic acid and tranexamic acid.

These drugs work by preventing the precursor, plasminogen, from becoming active plasmin.

They effectively hide the scissors.

I like that.

Because of this mechanism, they are fantastic at preventing recurrent bleeding.

But they aren't very useful for stopping an active ongoing bleed.

They are particularly valuable for mucous membrane bleeds or dental extractions, where the body's natural clot dissolving activity is notoriously high.

Got it.

Now for the biggest hurdle in hemophilia care managing inhibitors.

This is a devastating complication.

When you constantly inject foreign factor proteins into a patient, their immune system might eventually recognize them as invaders.

It mounts an attack, producing specific antibodies against the factor.

And we call these antibodies inhibitors.

Right.

They neutralize the replacement factor entirely, rendering the incredibly expensive treatment completely useless.

The text notes this happens most often in severe hemophilia A.

And there is a troubling demographic disparity.

The risk of developing inhibitors is unusually high, sometimes up to 50%, among African American and Hispanic patients.

We measure the strength of these inhibitors using the Bethesda Essay.

The result is expressed in Bethesda units, or BU.

It essentially measures how much of the patient's plasma it takes to neutralize a set amount of normal factor.

So if a patient develops a low, tighter of inhibitors, one option is immune tolerance therapy, or ITT.

How does ITT work?

Do we suppress their whole immune system?

Not exactly.

Think of it like aggressive allergy shots.

ITT involves repeatedly administering huge, overwhelming doses of the factor over an extended time.

You are essentially trying to exhaust the immune system, forcing it to eventually recognize the protein as normal and build a tolerance to it.

But what if ITT fails?

You have a patient who is actively bleeding, and if you give them standard factor, their inhibitors will just destroy it immediately.

That is when you use bypassing agents.

If the main road is blocked by an inhibitor, you take a detour, you bypass the need for factor VIII entirely.

The two preferred treatments are activated factor VII, known as factor VIII, and anti -inhibitor coagulant complex, or AICC.

Factor AIA is recombinant.

It works by directly acting on factor X, catalyzing it into its active form, and kickstarting the end of the cascade, completely bypassing the intrinsic pathway.

An AICC, brand name FIBA, works differently.

It is made from pooled human plasma and contains variable amounts of factors II, VII, IX, X, and X in both their activated and non -activated forms.

Injecting a cocktail of already activated clotting factors directly into the blood doesn't that risk causing way too much clotting?

It does, and that is a serious danger.

AICC carries a distinct risk of severe thrombotic complications,

specifically myocardial infraction heart attacks and disseminated intravascular coagulation, or DIC, where the blood clots systemically throughout the body.

Building on that, this explains the massive warning we talked about earlier with emesisimab.

If a patient is on hemlobra, which is constantly forcing factors together to clot, and you suddenly inject AICC, which is a massive payload of pre -activated factors.

You're throwing jet fuel on a fire.

The coagulation cascade goes into overdrive, leading to life -threatening thromboembolism.

So let's bring all of this pharmacology directly to the bedside.

For you listening, what are the major nursing implications for managing these patients safely?

It always starts with baseline clinical priorities.

Before you initiate any of these therapies, you need to obtain baseline factor levels.

And you continuously evaluate your success by monitoring the clinical response.

Is the prophylactic regimen actually preventing bleeds, or is the on -demand dose controlling the act of hemorrhage?

Patient education is absolutely massive here.

You must fiercely reinforce the avoidance of aspirin and first -generation NSAIDs to every patient and their family.

Because so much of this therapy is administered at home, the nurse is the primary educator.

You are teaching parents strict hand -washing protocols.

You are teaching them how to do that body weight math and calculate exact dosages.

You're teaching them how to reconstitute the sterile powder safely, the physical technique of 5 -E infusion via central port, and a vital administrative task recording the manufacturer, the brand name, the lot number, and the expiration date every single time they give a dose.

Yeah, that meticulous lot number tracking is a direct legacy of the 1980s contamination crisis.

If a batch of plasma -derived or even recombinant factor is ever compromised, public health officials need to know exactly who received it immediately.

Mastering this step -by -step logic, understanding why the intrinsic pathway fails, calculating the math of an IV push, knowing exactly why aspirin is forbidden,

that is how a nurse moves from memorizing a textbook to safely empowering patients in the real world.

Well said.

And as we look to the future, the entire landscape of that real world is shifting dramatically.

Which brings us to a final thought for you to ponder.

We talked about roctavian, the gene therapy shifting the paradigm.

It takes hemophilia from a lifelong chronic condition that requires up to $150 ,000 a year in regular infusions and turns it into a potential single -dose $2 million cure.

Yeah, if gene therapy becomes the new standard of care, how will the day -to -day role of the nurse transform?

Exactly.

Will you shift away from teaching anxious parents how to access the central IV line in their kitchen and instead find yourself primarily monitoring long -term genetic outcomes and immune responses?

It's a profound shift.

The science is rewriting the Rube Goldberg machine entirely.

Instead of constantly handing the patient the missing gear every other day, we are installing the factory to build the gear right inside their own liver.

It's wild to think about.

Thank you so much for exploring this deep dive with us today from the Last Minute Lecture team.

Thank you for listening.

See you next time.